Biopharmaceutical company RedHill Biopharma Ltd (Nasdaq:RDHL) on Monday provided the data from its Phase 2 positive safety and efficacy data for oral opaganib in 40 hospitalised patients in the US with COVID-19 pneumonia at World Microbe Forum (WMF) 2021.
According to the company, Opaganib (Yeliva, ABC294640) is a novel and patented selective inhibitor of sphingosine kinase 2 (SK2) that is administered orally, with a unique effect demonstrated of dual anti-inflammatory and antiviral activity that targets a component of the host cell of viral replication, potentially minimizing the likelihood of viral resistance.
The company said the results and post hoc analysis of data from the phase 2 study were presented through a poster titled Opaganib, an Oral Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: A Randomized, Double-blind, Placebo-controlledPhase 2A Study, in AdultSubjectsHospitalizedwith SARS-CoV-2 Positive Pneumonia ( NCT: 04414618 ).
About 86.4% of patients receiving the company's opaganib treatment were discharged from the hospital on day 14, from 55.6% of patients receiving placebo. About 81.8% of patients treated with opaganib achieved a two point improvement on the WHO Ordinal Scale, over 55.6% of patients who were part of the placebo group, achieved with a mean time of six days compared to seven and half days, respectively.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007